alanine and plitidepsin

alanine has been researched along with plitidepsin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Avilés, P; Batra, J; Bouhaddou, M; Coughlan, L; Dejosez, M; Fabius, JM; García-Sastre, A; Guillén, MJ; Jangra, S; Kehrer, T; Krogan, NJ; Losada, A; Martinez-Romero, C; Miorin, L; Moreno, E; Obernier, K; Rathnasinghe, R; Rojc, A; Rosales, R; Schotsaert, M; Shokat, KM; Uccellini, MB; Vignuzzi, M; White, KM; Yildiz, S; Zwaka, T	1
Ledford, H	1

Other Studies

2 other study(ies) available for alanine and plitidepsin

Article	Year
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science (New York, N.Y.), 2021, 02-26, Volume: 371, Issue:6532 Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Coronavirus Nucleocapsid Proteins; COVID-19; COVID-19 Drug Treatment; Depsipeptides; Drug Evaluation, Preclinical; Female; HEK293 Cells; Humans; Lung; Mice, Inbred C57BL; Mutation; Peptide Elongation Factor 1; Peptides, Cyclic; Phosphoproteins; RNA, Viral; SARS-CoV-2; Virus Replication	2021
Hundreds of COVID trials could provide a deluge of new drugs. Nature, 2022, Volume: 603, Issue:7899 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication	2022

Article

Year

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

Science (New York, N.Y.), 2021, 02-26, Volume: 371, Issue:6532

Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Coronavirus Nucleocapsid Proteins; COVID-19; COVID-19 Drug Treatment; Depsipeptides; Drug Evaluation, Preclinical; Female; HEK293 Cells; Humans; Lung; Mice, Inbred C57BL; Mutation; Peptide Elongation Factor 1; Peptides, Cyclic; Phosphoproteins; RNA, Viral; SARS-CoV-2; Virus Replication

2021

Hundreds of COVID trials could provide a deluge of new drugs.

Nature, 2022, Volume: 603, Issue:7899

Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication

2022